In their first of our annual SITC Preview series for 2022 we are going to be focusing on addressing a critical issue, which has long stumped many a researcher.

Fall in Boston

I’m not a bit fan of combining two agents just because that’s what any given company has in their pipeline and trying to justify some vague rationale of what might work. This is akin to throwing spaghetti or mud at the wall and hoping something will stick – it’s a rather basic, if not crude, way to proceed with clinical development and relies more on hope than reason for success.

What if we looked at the data available from patients tumours and learned from the information instead?

This sounds obvious, yet few actually attempt a deep dive on this critical endeavour.

The good news is some companies making progress and are seeking to address the underlying biology of what lies beneath – as these examples we have selected highlight nicely…

To continue reading our latest discussion on oncology new product development plus expert commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by